← Back to Search

Other

PH94B for Adjustment Disorder

Phase 2
Waitlist Available
Research Sponsored by VistaGen Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is designed to study whether the administration of PH94B nasal spray four times per day is an effective treatment for Adjustment Disorder with Anxiety symptoms in adults. The trial will last 6 to 10 weeks, and subjects will be given either the PH94B spray or a placebo.

Eligible Conditions
  • Adjustment Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hamilton Anxiety Scale
Secondary outcome measures
Clinical Global Impression - Improvement rating (CGI-I)
International adjustment disorder questionnaire (IADQ)
Sheehan Disability Scale

Trial Design

2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Intranasal spray four times a day for 28 days
Group II: PH94BExperimental Treatment1 Intervention
Intranasal spray 3.2 micrograms four times a day for 28 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
PH94B
Not yet FDA approved

Find a Location

Who is running the clinical trial?

VistaGen Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
1,544 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~12 spots leftby Apr 2025